Tirofiban decreases the risk for early neurologic deterioration in patients with noncardioembolic stroke who are seen within 24 hours of symptom onset.
Full results of the ANNEXA-I trial, showing better control of hematoma expansion but an increase in thrombotic events with andexanet vs usual care, are now published in NEJM.